Moyamoya disease involves progressive narrowing or occlusion of the terminal internal carotid artery and/or proximal anterior or middle cerebral arteries, together with abnormal basal collateral vessels on vascular imaging. The study included only people without clinically overt ischemic stroke or intracranial hemorrhage before enrollment, making the cohort a model of chronic cerebral hypoperfusion with less interference from major infarction or hemorrhagic injury. The retrospective observational design and complete-case analysis mean that the results cannot establish causation or determine whether either MRI measure predicts subsequent cognitive change. The researchers also noted that asymptomatic moyamoya disease is not necessarily free of structural white-matter injury or subtle cognitive impairment.

Participants had a mean age of 44.22 years, and the cohort included 34 women and 25 men. Mean MoCA and MMSE scores were 22.63 and 26.12, respectively. The mean ALPS index was 1.42, and the mean PVeD index was 0.48. Angiographic involvement was bilateral in 43 patients, or 72.9%, and unilateral in 16, or 27.1%. Maximum hemispheric Suzuki stage ranged from 1 to 4, with a median of 3. Median left and right Suzuki stages were both 2, and a paired Wilcoxon signed-rank test did not show a significant left-right difference in angiographic severity, with P = 0.095. The total white-matter hyperintensity score had a median of 3, an interquartile range of 2–5 and an observed range of 0–9.

MRI was acquired on a 3.0-tesla Siemens MAGNETOM Prisma scanner using a 64-channel head and neck coil. The protocol included three-dimensional T1-weighted imaging, axial T2-weighted imaging, fluid-attenuated inversion recovery, susceptibility-weighted imaging and diffusion tensor imaging. DTI data underwent correction for susceptibility-related distortion, eddy-current effects and participant motion. Tensor maps were then registered to MNI152 standard space for ALPS region-of-interest placement and parameter extraction. Visual quality control excluded images with substantial motion, signal loss, severe distortion, incomplete brain extraction, failed correction or unacceptable registration.

For DTI-ALPS, fixed bilateral regions of interest were placed at the level of the bodies of the lateral ventricles in projection- and association-fiber regions. The left and right indices were calculated as the mean of diffusivity along the x axis in the projection and association regions divided by the mean of y-axis diffusivity in the projection region and z-axis diffusivity in the association region. The mean ALPS index was the arithmetic average of the bilateral values. PVeD was calculated with the automated EstPVeD pipeline in MATLAB R2024a and SPM12. It registers a lateral-ventricle template to diffusion space, constructs an anatomically adaptive periventricular region and uses tissue segmentation to exclude cerebrospinal fluid and non-brain tissue. The transverse tensor ratio was calculated as Dxx divided by the square root of Dxx squared plus Dyy squared plus Dzz squared, with median values extracted from the left and right periventricular regions.

Before adjustment for confounding, mean ALPS was positively correlated with MoCA at Spearman rho = 0.493 and with MMSE at rho = 0.326. The left ALPS index correlated with MoCA at rho = 0.522 and MMSE at rho = 0.372, while right ALPS correlated with MoCA at rho = 0.335 but not MMSE. After adjustment for age and sex, the partial correlation for mean ALPS was 0.494 with MoCA and 0.316 with MMSE. Left ALPS remained associated with both scores, with partial rho values of 0.508 and 0.346, and right ALPS remained associated with MoCA at partial rho = 0.349. Right ALPS was not significantly associated with MMSE after correction, with partial rho = 0.203 and q = 0.2229. These results indicate that the imaging-cognition relationship was stronger and more consistent for ALPS than for PVeD in this sample.

PVeD showed a less consistent pattern in the unadjusted analysis. Left PVeD correlated with MMSE at rho = 0.320, while its association with MoCA was close to the corrected threshold, with q = 0.0526. Mean PVeD had a nominal association with MMSE at rho = 0.257, P = 0.0496, but it did not survive correction, with q = 0.0743. Mean PVeD was not significantly associated with MoCA, with rho = 0.246 and q = 0.0805. Following age and sex adjustment, none of the six PVeD associations met the false-discovery-rate threshold. Mean PVeD had partial rho values of 0.147 with MoCA and 0.182 with MMSE. Left PVeD and MMSE had a partial rho of 0.243, but q = 0.1365, while the other adjusted PVeD correlations were also non-significant after correction.

Multivariable linear regression produced a similar pattern. In models adjusted for age and sex, mean ALPS was associated with MoCA with an unstandardized beta of 11.716, a 95% confidence interval of 4.930 to 18.502, P = 0.0011 and adjusted R-squared of 0.233. Its association with MMSE was also nominally significant, with beta = 5.213, 95% confidence interval 0.619 to 9.807 and P = 0.0269. Mean PVeD was not significantly associated with MoCA, with beta = 34.662, 95% confidence interval −1.697 to 71.022 and P = 0.0613. Its MMSE association was nominal, with beta = 23.944, 95% confidence interval 0.735 to 47.153 and P = 0.0434. The regression P values were exploratory and were not additionally adjusted for multiple testing.

Adding total white-matter hyperintensity burden attenuated the ALPS-MMSE relationship to non-significance, with beta = 3.739, 95% confidence interval −0.897 to 8.375 and P = 0.1117. The ALPS-MoCA association remained statistically significant, with beta = 9.281, 95% confidence interval 2.512 to 16.051, P = 0.0081 and adjusted R-squared of 0.301. Mean PVeD was not associated with either cognitive score after WMH adjustment. In an extended model adding maximum hemispheric Suzuki stage to age, sex and WMH burden, mean ALPS remained associated with MoCA, although the estimate was smaller: beta = 7.790, 95% confidence interval 0.816 to 14.765, P = 0.0293 and adjusted R-squared of 0.317. ALPS-MMSE and both PVeD associations were non-significant in those extended models. The sensitivity analyses therefore suggest that structural white-matter injury and angiographic severity account for part, but not necessarily all, of the imaging-cognition relationships.

Several limitations constrain the findings. The sample was relatively small and cross-sectional, so the associations cannot establish causality, longitudinal predictive value or the direction of any imaging-cognition relationship. APOE genotype and amyloid-beta or tau biomarkers were unavailable, meaning occult Alzheimer’s pathology, mixed vascular-neurodegenerative disease and APOE-related effects could not be excluded. Education level was also unavailable and may have influenced MoCA and MMSE performance. Although WMH burden and maximum hemispheric Suzuki stage were included, potential confounders including ventricular volume, brain atrophy, lacunes, cerebral microbleeds, quantitative cerebral perfusion and cerebrovascular reserve were not quantitatively modeled. MoCA and MMSE are global screening instruments rather than comprehensive neuropsychological tests, so the absence of a PVeD association with global scores does not exclude relationships with executive function, processing speed, attention or memory.

The biological meaning of the two metrics also requires caution. In chronic hypoperfusion, periventricular diffusion may reflect white-matter injury, demyelination, tissue rarefaction, ventricular enlargement, altered tissue water content, ischemia-related changes and potentially interstitial fluid transport. PVeD was introduced as a marker associated with amyloid burden and cognition in the Alzheimer’s disease continuum, but the present study shows that its relationship with global cognition was less consistent in a chronic-ischemic population. ALPS is not a direct measure of glymphatic flow either: it can be influenced by fiber architecture, crossing fibers, region-of-interest placement, scanner parameters and disease-related tissue changes. Agreement between ALPS and tracer-based MRI measures of cerebrospinal fluid distribution and clearance remains limited. The study therefore supports a disease-specific, structurally informed interpretation of diffusion-based markers rather than a claim that one index is a superior measure of true glymphatic function. Prospective studies combining longitudinal cognition, perfusion and vascular-injury measures, Alzheimer’s biomarkers and tracer-based fluid assessments will be needed to clarify what each index reflects and whether either predicts cognitive trajectories.

Subject of Research: Cross-sectional comparison of DTI-ALPS and periventricular diffusivity with cognition in asymptomatic moyamoya disease

Article Title: Disease-context dependence of periventricular diffusivity and DTI-ALPS in asymptomatic moyamoya disease

Article References: Liu, H., Liu, X., Ji, H., Xiao, A., & Liu, Y. (2026). Disease-context dependence of periventricular diffusivity and DTI-ALPS in asymptomatic moyamoya disease. Frontiers in Neurology, 17, 1927018. https://doi.org/10.3389/fneur.2026.1927018

Image Credits: AI Generated

DOI: 10.3389/fneur.2026.1927018

Keywords: moyamoya disease, DTI-ALPS, periventricular diffusivity, diffusion MRI, chronic hypoperfusion, brain fluid transport, cognitive impairment, white matter injury, vascular cognitive impairment, glymphatic system, Disease-context, dependence

The experimental framework was built around primary rat microglia exposed to 1 percent oxygen, a level that mimics the severe hypoxia seen in ischemic white-matter injury. Under these conditions, the microglia underwent a striking activation. The intensity of ionized calcium-binding adaptor molecule 1, a hallmark protein of activated microglia, rose 2.82-fold compared with normoxic controls. At the same time, extracellular lactate concentrations climbed from 27.4 plus or minus 2.3 to 48.5 plus or minus 5.2 micromoles per milliliter, nearly doubling the metabolic signal available to neighboring cells. These numbers establish that hypoxia does not merely activate microglia morphologically; it fundamentally rewires their metabolism toward glycolytic lactate production.

To test what this metabolic shift does to oligodendrocyte-lineage cells, the team used conditioned-medium and Transwell models in which recipient cells were exposed to factors released by hypoxic microglia. The consequences were dramatic. Recipient-cell apoptosis increased from 9.1 plus or minus 0.8 percent to 39.0 plus or minus 1.3 percent, a more than fourfold rise in programmed cell death. Meanwhile, myelin basic protein fluorescence, a proxy for the myelinating capacity of these cells, collapsed from 1.00 plus or minus 0.08 to 0.35 plus or minus 0.05. In other words, the cells were not just dying; the survivors were losing the molecular machinery needed to wrap axons in myelin.

The investigators then turned to small extracellular vesicles, nanoscale lipid bilayer particles that cells release to shuttle proteins, lipids, and genetic material between one another. When oligodendrocyte-lineage cells were exposed to hypoxia-conditioned sEVs, a similar injury phenotype emerged, suggesting that these vesicles carry much of the damaging signal from hypoxic microglia. The critical question was whether lactate itself was the cargo responsible. To answer it, the researchers treated donor microglia with oxamate, an inhibitor of lactate dehydrogenase that blocks the conversion of pyruvate to lactate. This intervention partially restored myelin basic protein fluorescence in recipient cells from 0.34 plus or minus 0.05 to 0.82 plus or minus 0.07, demonstrating that lactate-associated metabolism in the donor cells is a major contributor to the injury cascade.

Perhaps the most mechanistically revealing finding concerns what happens inside the recipient cells when they encounter lactate-laden vesicles. Hypoxia-conditioned microglia caused recipient-cell Toll-like receptor 4 mRNA to rise 5.6-fold, indicating a powerful transcriptional upregulation of this innate immune receptor. Even more striking, the team measured histone H3 lysine 18 lactylation enrichment at the TLR4 promoter, a epigenetic modification in which lactate-derived lactyl groups attach to histone tails and alter gene expression. Enrichment climbed from 0.9 plus or minus 0.1 to 7.1 plus or minus 0.9, an almost eightfold increase. Both the mRNA upregulation and the promoter lactylation were attenuated by oxamate, tying the epigenetic activation of TLR4 directly to lactate availability.

This lactylation mechanism represents a relatively new frontier in neuroimmunology. Histone lactylation was first described as a way that metabolic state can be written directly into chromatin, allowing glycolysis-derived lactate to act as an epigenetic signal rather than merely a waste product. In this study, the lactylation of histone H3 lysine 18 at the TLR4 promoter suggests that lactate carried by hypoxic microglial vesicles does not simply activate TLR4 from the outside; it reprograms the recipient cell’s genome to produce more of the receptor, creating a self-amplifying inflammatory loop. The authors note that this framework is testable and does not establish a single linear causal pathway, but the concordance between the metabolic, epigenetic, and inflammatory measurements is compelling.

To confirm that TLR4 signaling is functionally required for the injury phenotype, the team used TAK-242, a selective TLR4 inhibitor that blocks the receptor’s downstream signaling without affecting ligand binding. When recipient cells were treated with TAK-242, apoptosis fell from 13.9 plus or minus 0.9 percent to 7.3 plus or minus 0.7 percent, nearly halving cell death. Myelin basic protein fluorescence rose to 1.82 plus or minus 0.14, exceeding even the normoxic baseline and suggesting that blocking TLR4 not only prevents injury but may actively promote myelination. These pharmacological results provide strong evidence that TLR4 is a critical node in the cascade from hypoxic microglial metabolism to oligodendrocyte-lineage cell damage.

The researchers also examined human transcriptomic datasets to see whether the rat-cell findings align with what happens in human disease. The analysis showed directionally concordant metabolic, inflammatory, and myelination changes, meaning that the same patterns of altered lactate metabolism, TLR4-related inflammation, and reduced myelination gene expression appear in human white-matter injury contexts. This cross-species concordance strengthens the argument that the mechanism identified in vitro is relevant to clinical ischemic white-matter injury, although the authors are careful to frame their conclusions as supporting a testable framework rather than proving a definitive causal chain.

The clinical implications of this work are substantial. Ischemic white-matter injury underlies much of the disability from stroke, vascular cognitive impairment, and perinatal brain injury, and oligodendrocyte loss is a central driver of the long-term damage. If lactate-associated extracellular vesicles from hypoxic microglia are indeed a major route of injury, then interventions that block lactate production in microglia, inhibit vesicle release or uptake, or antagonize TLR4 signaling could protect myelin-forming cells and preserve white matter integrity. TAK-242 and related TLR4 inhibitors are already being explored in other neurological contexts, and oxamate-like strategies that modulate lactate dehydrogenase activity represent a complementary metabolic approach.

The study also adds to a growing body of evidence that extracellular vesicles are not passive cellular debris but active messengers that can carry pathological signals between glial cells. Previous work has shown that microglial vesicles can either promote or inhibit myelin repair depending on their cargo and the activation state of the parent cell. This research identifies lactate-associated metabolism as a specific determinant of whether hypoxic microglial vesicles become injurious, opening the possibility that manipulating the metabolic state of microglia before vesicle release could convert damaging vesicles into protective ones. As the field moves forward, the challenge will be to translate these in vitro findings into animal models and eventually into therapies that can be deployed in the narrow therapeutic window following ischemic events.

Subject of Research: Lactate-associated extracellular vesicles from hypoxic microglia induce oligodendrocyte injury via TLR4 signaling

Article Title: Hypoxic microglia induce oligodendrocyte injury through lactate associated extracellular vesicles and toll like receptor four signaling

Article References: Wen, Y., Li, D., Lin, J., Li, T., & Jin, X. (2026). Hypoxic microglia induce oligodendrocyte injury through lactate associated extracellular vesicles and toll like receptor four signaling. 3 Biotech, 16(11), Article 469. https://doi.org/10.1007/s13205-026-05095-1

Image Credits: AI Generated

DOI: 10.1007/s13205-026-05095-1

Keywords: microglia, oligodendrocyte, lactate, extracellular vesicles, TLR4, hypoxia, white matter injury, myelin, Hypoxic, induce, injury, associated

AESD is the most common infection-triggered encephalopathy in East Asian children, typically erupting after prolonged febrile seizures. Its signature is cruel timing: an initial seizure phase is followed by a deceptive period of apparent recovery, and then, days later, a second cluster of seizures coincides with the emergence of distinctive MRI changes in the brain’s white matter. Even with therapeutic hypothermia—deliberate cooling of the body to slow metabolic injury—lasting neurological deficits remain common, and existing neuroprotective strategies are limited. For families and clinicians confronting the condition, the therapeutic landscape has remained stubbornly barren.

The pathophysiology of AESD is incompletely understood, but the prevailing view holds that excitotoxic white matter injury is triggered by extracellular glutamate released during early febrile status epilepticus, with subcortical damage appearing days later. That delayed secondary injury phase has attracted intense interest as a therapeutic target, because it opens a window during which intervention might still alter the trajectory of brain damage. Remote ischemic postconditioning, abbreviated RIPoC and also called remote ischemic conditioning, fits this window remarkably well.

The technique itself sounds almost too simple to be credible. A blood pressure cuff is inflated on a limb—here, the lower extremity at 200 mmHg—cutting off blood flow for five minutes before being deflated to allow reperfusion. The cycle is repeated several times. This controlled, repeated ischemia and reperfusion at a distant site triggers cascades of protective signaling that reach the brain through neuronal, humoral, and immune pathways. In rodent and piglet models of neonatal hypoxic-ischemic encephalopathy, the approach has been shown to reduce cerebral edema, attenuate neuroinflammation and oxidative stress, stabilize the blood-brain barrier, and preserve white matter integrity, as measured by cerebral ATP levels and lactate-to-N-acetylaspartate ratios. Those mechanisms closely resemble the pathological features of AESD, providing a reasonable biological rationale for testing the technique outside its traditional ischemia-reperfusion context.

The trial under scrutiny, conducted by Kawano and colleagues, enrolled a prospective single-arm cohort of children with AESD and compared outcomes against a historical control group from the same center. Remote ischemic postconditioning was administered as four cycles of five-minute cuff inflation and deflation to one lower extremity, starting at the initiation of therapeutic hypothermia. The safety results were unambiguous: no thrombotic events, no hemodynamic instability, and no coagulation disturbances were recorded. The only adverse finding was transient skin redness at the cuff site. Safety data from pediatric RIC trials in neonatal encephalopathy, cardiac surgery, and necrotizing enterocolitis have been similarly reassuring, and this report adds AESD to that growing list. Taken together, the commentators argue, there is now sufficient basis to proceed to randomized trial design in this population.

The outcome data, however, demand a more cautious reading. The Kyoto Scale of Psychological Development, the neurodevelopmental assessment used in the study, did not differ significantly between groups across any developmental domain, though the RIPoC group showed numerically higher scores overall in postural-motor, cognitive-adaptive, and language-social developmental quotients. Multiple linear regression identified a lower Tada score—a measure of illness severity—and RIPoC receipt as independent predictors of better developmental outcomes. But Kalish and Robertson urge restraint here: the model contains four predictor variables across only 25 patients and is substantially underpowered. The different time periods of the two cohorts also introduce confounding from changes in supportive care and neuroimaging practice that cannot be fully controlled. These limitations do not compromise the safety findings, but the commentators suggest the multivariate signal should not be read as preliminary efficacy evidence.

Dosing presents another open question that could determine whether the technique ever delivers measurable benefit. The protocol used in the AESD study—a single session of four cycles to one lower extremity—is considerably less intensive than the bilateral upper-limb, five-cycle-twice-daily regimen applied for 10 to 14 days in the RICAMIS trial of adult acute ischemic stroke, which was published in JAMA in 2022. Whether a single brief application activates the relevant neuronal, humoral, and immune pathways to a clinically meaningful degree is simply not known, and a more intensive schedule may ultimately be needed. Timing matters as well: arterial spin-labelling studies have documented hypoperfusion within 24 hours of early seizures in some AESD patients, before the MRI changes and late seizure cluster that define the clinical syndrome. That perfusion abnormality suggests a narrow early window in which conditioning stimuli might need to be delivered to do any good.

Measurement poses its own challenge for the field. The Kyoto Scale of Psychological Development is well validated within Japan and covers the right age range for AESD patients, but its limited international uptake will complicate cross-national trial design. Future multicenter studies, the commentators argue, should include internationally recognized developmental measures alongside the KSPD to enable pooled analyses and meet regulatory expectations outside East Asia. Without such harmonization, the evidence base risks fragmenting along geographic lines just as the technique approaches its decisive tests.

What makes remote ischemic conditioning so attractive—especially in pediatrics—is its radical practicality. It requires only a blood pressure cuff, no additional pharmacology, no anesthesia, and is inexpensive enough to be deployed in low-resource settings where advanced neurocritical care is scarce. The accumulating safety record now spans neonatal hypoxic-ischemic encephalopathy, cardiac surgery, moyamoya disease, necrotising enterocolitis, and now AESD, each representing a distinct pathophysiological context. The absence of harm across this remarkably diverse range is itself informative, and it matters particularly when treating children, in whom any treatment-related risk demands a high threshold of justification.

The path forward, according to the commentary, is a randomized controlled trial in a larger, multicenter AESD cohort, with a protocol that refines the timing, cycle number, duration, and laterality of the conditioning stimulus, and uses internationally validated primary outcome measures. Biomarker sub-studies measuring inflammatory markers, oxidative stress, and neuroimaging correlates of white matter injury would help identify which patients benefit most and clarify the underlying mechanism. Kalish and Robertson credit Kawano and colleagues with doing what a good pilot study should do: establishing safety, raising a plausible efficacy signal, and defining the questions a definitive trial needs to answer. For a condition where treatment options remain limited and the children affected are among the most vulnerable, a blood pressure cuff may yet prove to be an unlikely instrument of neuroprotection.

Subject of Research: Safety and feasibility of remote ischemic conditioning as adjunctive neuroprotection in acute pediatric neurological conditions

Article Title: Accumulating safety data for remote ischemic conditioning in acute pediatric neurological conditions

Article References: Kalish, B. T., & Robertson, N. J. (2026). Accumulating safety data for remote ischemic conditioning in acute pediatric neurological conditions. Pediatric Research. https://doi.org/10.1038/s41390-026-05402-9

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05402-9

Keywords: remote ischemic conditioning, AESD, pediatric encephalopathy, therapeutic hypothermia, neuroprotection, febrile status epilepticus, white matter injury, Pediatric Research, clinical trial design, neonatal encephalopathy, blood pressure cuff, hypoperfusion

The research, published in Pediatric Research, focused on infants born between roughly 22 and 28 weeks of gestation, the very edge of viability. Thanks to advances in neonatal intensive care, a growing number of these babies now survive, but a substantial proportion go on to face cognitive, behavioral, and motor impairments. Clinicians have long searched for early, reliable markers that could identify at-risk infants while interventions are still possible. Cerebral magnetic resonance imaging performed at term-equivalent age, the point at which a preterm infant reaches what would have been full gestational maturity, has emerged as a powerful window into the developing brain, offering far greater sensitivity than cranial ultrasound for detecting injuries in posterior and infratentorial structures, including the brainstem itself.

In the retrospective cohort study, the team analyzed infants admitted to the level IV neonatal intensive care unit at the Medical University of Vienna between August 2017 and December 2022, all of whom had undergone routine cerebral MRI before hospital discharge. From an initial pool of 315 extremely preterm infants scanned during their stay, 295 had imaging between 35 and just under 42 weeks of postmenstrual age. The median gestational age at birth was just under 26 weeks, and the mean birthweight a mere 790 grams, figures that underscore just how early this cohort entered the world. Scans were carried out on a 1.5 Tesla scanner without sedation, using a feed-and-wrap technique with a vacuum fixation mattress and ear protection so that infants could be imaged during natural sleep.

The technical heart of the study lies in its measurement protocol. Working from the midsagittal T2-weighted slice, the single midline image that cuts the brainstem lengthwise, researchers traced discrete regions of interest around each brainstem compartment. The midbrain was divided into two zones separated by the aqueduct of Sylvius, the anterior basis mesencephali and the posterior tegmentum. The pons, the prominent bulge through which vast numbers of corticocerebellar fibers pass, was outlined from its junction with the midbrain down to the pontomedullary junction. The medulla oblongata, which continues downward to the obex, was encircled along its dorsal and ventral boundaries. Reference values and z-scores were generated from 242 infants who showed no severe brain injury, meaning no high-grade intraventricular hemorrhage, no high-grade cerebellar hemorrhage, and no cystic white matter damage, and were stratified by gestational age at birth and at scanning. Repeated measurements confirmed very good intra- and interobserver reliability, with correlation coefficients of at least 0.81.

The results paint a picture of a brainstem that is both a mirror of maturity and a barometer of injury. Brainstem size increased steadily with gestational age, and infants born at 22 or 23 weeks, the threshold of viability, had the smallest measurements at term-equivalent age. More striking was the effect of neonatal brain injury. Median brainstem z-scores fell progressively with hemorrhage severity: infants without intraventricular hemorrhage scored a median of 0.13, those with low-grade bleeds 0.06, and those with high-grade hemorrhages a markedly lower negative 0.51. When the researchers grouped infants with any severe pathology, including severe hemorrhage, cerebellar bleeding, or cystic white matter injury, brainstem z-scores were significantly reduced compared with the reference cohort, with a large effect size corresponding to a Cohen’s d of 0.96. The measurements, in other words, capture global injury severity rather than isolated brainstem damage.

This pattern makes anatomical sense. The pons in particular is packed with crossing fibers that connect the cerebral cortex and cerebellum, alongside spinocerebellar and corticospinal tracts. A severe hemorrhage early in the neonatal period can unleash blood toxicity, neuroinflammation, and secondary disruption of white matter development that reverberates far beyond the site of the original bleed. A smaller brainstem at term-equivalent age may therefore reflect impaired maturation of widespread neural connectivity, a shrunk cross-section of the brain’s entire communication architecture. This interpretation helps explain why a structure that seems so remote from cognition and voluntary movement can nevertheless track developmental outcomes so closely.

And track them it does. Follow-up data at two years’ corrected age were available for about 83 percent of the cohort, assessed with the Bayley Scales of Infant and Toddler Development, third edition, using the German normative dataset and administered by certified clinical psychologists. In the reference collective of infants without severe brain injury, after adjustment for gestational age at birth and at scanning, sex, birthweight, sepsis, surgical closure of a persistent ductus arteriosus, necrotizing enterocolitis, severe retinopathy of prematurity, bronchopulmonary dysplasia, hemorrhage grade, cerebellar hemorrhage, and white matter injury, higher brainstem z-scores remained independently associated with better cognitive and motor composite scores. Each unit increase in brainstem z-score corresponded to roughly 3.6 points of cognitive score and 2.8 points of motor score. Language showed a borderline trend that narrowly missed statistical significance in this group.

When the analysis was repeated in the full cohort, including infants with severe brain injuries, the associations grew even stronger: the adjusted effects rose to about 5.1 points for cognition, 4.3 for language, and 5.7 for motor outcomes, all statistically robust. Among the four brainstem compartments, only the pons remained independently linked to cognitive and motor outcomes in the regional analysis, likely because its larger size yields more reliable measurements than the smaller midbrain and medullary segments. Meanwhile, the search for risk factors associated with a brainstem size below the tenth percentile turned up telling clues: infants with lower birthweight z-scores, higher first neonatal lactate levels, and lower first-minute APGAR scores were more likely to fall in that bottom decile, pointing to both fetal growth restriction and early hemodynamic stress as contributors. Notably, previously suspected factors such as infections and bronchopulmonary dysplasia did not reach statistical significance in this cohort.

The appeal of this biomarker lies in its simplicity. Unlike advanced quantitative techniques such as diffusion tensor imaging or myelination mapping, which demand specialized post-processing and expertise, tracing a handful of regions on a single midline slice takes minutes and uses standard radiology software available in any imaging department. That makes it an attractive candidate for routine clinical use in neonatal units that already perform term-equivalent MRI, allowing a rough but meaningful developmental risk stratification long before formal psychological testing becomes possible. If a baby’s brainstem z-score flags concern at 38 weeks, early intervention services, which are known to benefit preterm infants, could be engaged months or even years earlier than they otherwise would be.

The authors are careful to note the study’s limits. It was retrospective and single-center, so unmeasured confounders cannot be excluded, and the reference values may not apply to other gestational or imaging ranges. Two-dimensional tracings, however practical, cannot fully capture the three-dimensional complexity of brainstem anatomy, and an observational design can never prove that a small brainstem causes poor outcomes rather than simply marking shared underlying pathology. External validation in independent cohorts is required before the measurements enter routine prognostication. Still, the study opens an intriguing path forward: combining these simple morphometric traces with functional MRI, quantitative myelination measures, and neurophysiological techniques could yield multimodal, individualized forecasts of brain development. For now, the message is compelling in its economy: one of the oldest and most vital structures in the human brain, measured with a digital cursor on a single scan, may quietly reveal how the whole developing brain is destined to grow.

Subject of Research: Brainstem MRI biometry and neurodevelopmental outcomes in extremely preterm infants

Article Title: Brainstem size in extremely preterm infants: reference values and association with neurodevelopmental outcomes

Article References: Buchmayer, J., Zeugswetter, P., Fuiko, R., Kasprian, G., Giordano, V., Klebermaß-Schrehof, K., Schmidbauer, V., Stummer, S., Berger, A., & Goeral, K. (2026). Brainstem size in extremely preterm infants: reference values and association with neurodevelopmental outcomes. Pediatric Research. https://doi.org/10.1038/s41390-026-05529-9

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05529-9

Keywords: brainstem, extremely preterm infants, cerebral MRI, term-equivalent age, intraventricular hemorrhage, neurodevelopment, Bayley-III, pons, reference values, biomarker, neonatology, white matter injury

The review, led by neonatologist Yunus E. Dogan of the University of Florida together with colleagues spanning neonatology, cardiac surgery, and radiology, integrated eleven prospective and retrospective cohort studies published between 2016 and 2025. Its central numbers are sobering. Preoperative brain injury, detected on magnetic resonance imaging performed before any surgical intervention, is found in between 12 and 54 percent of neonates with congenital heart disease. That enormous range reflects differences in lesion definitions, imaging protocols, and cardiac diagnoses across studies, but even the most conservative estimates mean that at least one in eight babies arrives at the cardiac operating table with a brain that has already been injured. After surgery, the burden persists, with new lesions appearing on postoperative scans in a substantial fraction of survivors.

The patterns of injury are distinctive and diagnostically revealing. Before surgery, the most common findings are white matter injury, arterial ischemic stroke, and cerebral hemorrhage. White matter injury, sometimes described as periventricular leukomalacia-like damage, strikes the fatty sheathed fibers that connect distant brain regions and are still being actively myelinated in the third trimester. After surgery, the imaging signature shifts: white matter injury remains dominant, but clinicians also see focal infarctions that are often thromboembolic in origin, tiny microhemorrhages scattered through the parenchyma, and cerebral venous thrombosis. This temporal fingerprint, captured by serial MRI, allows researchers to distinguish lesions that were present at birth from those acquired in the operating room or intensive care unit, and it has fundamentally changed the framing of the problem from a surgical complication to a continuum of vulnerability that begins in utero.

Why is the fetal brain so fragile when the heart is malformed? The answer lies in the peculiar plumbing of fetal circulation and the metabolic demands of the rapidly growing brain. In a normal fetus, the placenta delivers oxygenated blood, and the brain enjoys a privileged, high-flow supply. In fetuses with critical heart defects, however, the anatomy reroutes this flow. In conditions such as hypoplastic left heart syndrome or transposition of the great arteries, oxygen-rich and oxygen-poor blood mix abnormally, and the cerebral circulation may be perfused at lower pressure, lower oxygen content, or both. Advanced fetal MRI studies have measured this directly, showing reduced fetal cerebral oxygen consumption associated with smaller brain size, delayed cortical development correlated with reduced oxygen delivery, and altered hemodynamic responses when mothers are given supplemental oxygen. The result is a brain that reaches birth with globally reduced volumes, microstructural abnormalities in structures like the corpus callosum, and in some cases aberrant functional connectivity detectable before any operation.

The maternal-fetal environment adds another layer of risk. The review highlights evidence linking placental dysfunction and preeclampsia to preoperative focal white matter injury in neonates with complex heart disease, an emerging field some researchers call neuroplacentology. Three-dimensional volumetric MRI of the placenta in fetuses with complex congenital heart disease has revealed measurable differences compared with controls, and placental pathology correlates with neuroimaging abnormalities after birth. In other words, the same compromised maternal-fetal conditions that stress the heart may simultaneously starve the developing brain of oxygen and nutrients. Perinatal and neonatal characteristics compound this vulnerability: male sex, prematurity, and low birth weight all emerge as risk factors, echoing patterns seen in preterm brain injury more broadly. Notably, the immature oligodendrocytes that build myelin in the third trimester are exquisitely sensitive to hypoxia-ischemia and inflammation, which helps explain why white matter bears the brunt of the damage in this population.

Cerebral autoregulation, the brain’s ability to maintain steady blood flow despite swings in blood pressure, appears to be impaired in many of these newborns even before surgery. Studies of preoperative infants with congenital heart disease have documented blunted autoregulatory capacity, and novel noninvasive measures of cerebrovascular stability are being tested against invasive monitoring to bring this physiology to the bedside. The clinical implication is profound: a blood pressure that is perfectly adequate for one baby’s brain may be dangerously low for another’s, and the transition from fetal to neonatal circulation, with its shifting shunts and falling pulmonary resistance, is a period of particular hazard. Preoperative procedures such as balloon atrial septostomy have been scrutinized as potential stroke triggers, though large studies suggest that oxygenation and time to surgery are more important determinants of injury than the procedure itself.

Then comes the operation, and with it a new set of insults. Cardiopulmonary bypass, the heart-lung machine that sustains circulation during repair, exposes the brain to nonphysiological flow, embolic debris, inflammatory activation, and ischemia-reperfusion injury when the heart is restarted. Neonatal blood is uniquely challenging in this setting: standard heparin doses achieve less consistent thrombin inhibition in newborns than in older patients, and the coagulation system swings between thrombosis and bleeding with little margin for error. Anticoagulation strategy, surgical timing, hemodynamic instability, and the use of extracorporeal membrane oxygenation all emerge in the review as procedural risk factors for postoperative brain injury. Focal infarctions after surgery are frequently thromboembolic, and cerebral sinovenous thrombosis has been documented in infants undergoing cardiac surgery, sometimes producing thalamic hemorrhage and requiring difficult anticoagulation decisions in a fragile patient.

There is, however, genuine cause for optimism embedded in the data. The review notes that advances in blood pressure management, tailored perfusion strategies, and optimized surgical timing have already reduced postoperative injury rates, and recent multicenter work has documented a declining incidence of postoperative neonatal brain injury over time. Studies comparing cohorts with different practice approaches show that institutional choices matter, and European collaborative data have begun to map which perioperative factors predict long-term neurodevelopmental outcomes better than conventional imaging alone. The stakes of these improvements are high: perioperative brain injury on neonatal MRI is associated with worse school-age neurodevelopment, reduced white matter volume predicts language difficulties, and hippocampal volume reductions in adolescents with congenital heart disease track with intellectual function. Survivors face elevated rates of motor delay, cognitive and executive function deficits, and abnormalities in brain regions regulating anxiety and mood.

The path forward, as the authors frame it, is precision neuroprotection across the entire continuum of care. Antenatal interventions, including maternal hyperoxia strategies being tested with blood oxygenation level dependent fetal MRI, could potentially bolster the fetal brain before birth. Individualized hemodynamic management targets, guided by continuous cerebral autoregulation monitoring rather than population-wide blood pressure thresholds, could protect the brain during bypass and in the intensive care unit. Multimodal neuromonitoring, incorporating continuous electroencephalography and amplitude-integrated EEG, which has been shown to predict preoperative MRI findings, could catch injury in real time. Risk-stratified anticoagulation could balance clot and bleeding risks, and neuroprotective drugs such as allopurinol are already in phase III randomized trials for babies requiring bypass surgery. Finally, long-term neurodevelopmental surveillance programs would ensure that early injuries, however subtle, are met with early intervention.

For the roughly one percent of newborns whose hearts form differently, the message of this synthesis is both a warning and a promise. The brain injury that shadows congenital heart disease is not an inevitable consequence of a defective heart, nor simply the price of a heroic operation. It is a mechanistically traceable process, visible on MRI from fetal life onward, driven by hypoxemia, impaired autoregulation, inflammation, and thrombosis, and shaped by the placenta, the delivery room, the bypass circuit, and the intensive care unit. Each of those checkpoints is now a target. If the trajectory of declining postoperative injury continues, and if antenatal and precision perioperative strategies mature from promising trials into standard care, the generation of children born with heart defects may one day keep their hearts repaired without paying a hidden neurological price.

Subject of Research: Brain injury mechanisms, MRI patterns, and perioperative risk factors in neonates with congenital heart disease

Article Title: Brain injury in congenital heart disease: pathophysiology, MRI patterns, and perioperative risk factors

Article References: Dogan, Y. E., Vargas-Boggiano, D. A., Bleiweis, M., Philip, J., Narasimhulu, S. S., Tuna, I., & Weiss, M. D. (2026). Brain injury in congenital heart disease: pathophysiology, MRI patterns, and perioperative risk factors. Pediatric Research. https://doi.org/10.1038/s41390-026-05454-x

Image Credits: AI Generated

DOI: 10.1038/s41390-026-05454-x

Keywords: congenital heart disease, brain injury, white matter injury, neonatal stroke, MRI, cardiopulmonary bypass, cerebral autoregulation, placental dysfunction, neuroprotection, neurodevelopmental outcomes, fetal circulation, thromboembolism